Quetiapine

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Generalized Anxiety Disorder

Conditions

Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment

Trial Timeline

Jan 1, 2008 → Aug 1, 2011

NCT ID

NCT00668265

About Quetiapine

Quetiapine is a approved stage product being developed by AstraZeneca for Generalized Anxiety Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00668265. Target conditions include Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment.

What happened to similar drugs?

5 of 20 similar drugs in Generalized Anxiety Disorder were approved

Approved (5) Terminated (2) Active (13)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄Perampanel + Placebo comparatorEisaiPhase 3

🔄PerampanelEisaiPhase 3

🔄CenobamateOno PharmaceuticalPhase 3

🔄Duloxetine + PlaceboEli LillyPhase 3

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01244711	Approved	Terminated	Sep 1, 2008	Sep 1, 2011	Major Depression
NCT00554658	Approved	Completed	Mar 1, 2008	Mar 1, 2011	Schizophrenia
NCT00668265	Approved	Terminated	Jan 1, 2008	Aug 1, 2011	Generalized Anxiety Disorder
NCT01458964	Approved	Completed	Jan 1, 2008	Dec 1, 2013	Fibromyalgia
NCT00681668	Phase 2	Terminated	Aug 1, 2007	Oct 1, 2008	Postpartum Depressive Disorder
NCT00486798	Phase 3	Terminated	May 1, 2007	Aug 1, 2007	Psychotic Disorders
NCT00407199	Approved	Completed	Dec 1, 2006	Sep 1, 2007	Social Phobia
NCT00388973	Phase 3	Completed	Sep 1, 2006	Dec 1, 2007	Major Depressive Disorder
NCT00302770	Phase 3	Terminated	Jun 1, 2006	Dec 1, 2006	Social Anxiety Disorder
NCT01224067	Approved	Completed	Mar 1, 2006	Oct 1, 2008	Social Anxiety Disorder
NCT00232570	Pre-clinical	UNKNOWN	Nov 1, 2005	Jan 1, 2010	Alzheimer's Disease
NCT00232414	Phase 3	Completed	Oct 1, 2005	Dec 1, 2007	Bipolar I Disorder
NCT00174603	Phase 3	Terminated	Aug 1, 2005	Jan 1, 2007	Major Depression With Psychotic Features
NCT00254813	Phase 3	Completed	Oct 1, 2004	Sep 1, 2005	Psychotic Disorders
NCT00252226	Phase 3	Completed	Jun 1, 2004	Dec 1, 2007	Bipolar Disorder
NCT00207064	Pre-clinical	Completed	Apr 1, 2004	Sep 1, 2008	Schizophrenia
NCT00536783	Pre-clinical	Completed	Apr 1, 2004	Mar 1, 2006	Schizophrenia
NCT00215254	Phase 2/3	Completed	Mar 1, 2004	Feb 1, 2006	Social Anxiety Disorder
NCT00156715	Approved	Completed	Mar 1, 2004	Oct 1, 2008	Schizophrenia
NCT00277667	Phase 3	Completed	Feb 1, 2004	Dec 1, 2007	Bipolar Disorder

Competing Products

20 competing products in Generalized Anxiety Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40